Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Targeting Cancer with Peptide RNAi Nanoplexes.

Mixson AJ, Leng Q, Chou ST, Woodle MC.

Methods Mol Biol. 2019;1974:161-180. doi: 10.1007/978-1-4939-9220-1_12.

PMID:
31099002
2.

Enhanced tumor uptake and activity of nanoplex-loaded doxorubicin.

Zhao N, Leng Q, Woodle MC, Mixson AJ.

Biochem Biophys Res Commun. 2019 May 21;513(1):242-247. doi: 10.1016/j.bbrc.2019.03.190. Epub 2019 Apr 4.

PMID:
30954222
3.

Advances in delivery systems for doxorubicin.

Zhao N, Woodle MC, Mixson AJ.

J Nanomed Nanotechnol. 2018;9(5). pii: 519. doi: 10.4172/2157-7439.1000519. Epub 2018 Nov 4.

4.

Targeted Delivery of siRNA Therapeutics to Malignant Tumors.

Leng Q, Woodle MC, Mixson AJ.

J Drug Deliv. 2017;2017:6971297. doi: 10.1155/2017/6971297. Epub 2017 Nov 9. Review.

5.

Simultaneous silencing of TGF-β1 and COX-2 reduces human skin hypertrophic scar through activation of fibroblast apoptosis.

Zhou J, Zhao Y, Simonenko V, Xu JJ, Liu K, Wang D, Shi J, Zhong T, Zhang L, Zeng L, Huang B, Tang S, Lu AY, Mixson AJ, Sun Y, Lu PY, Li Q.

Oncotarget. 2017 Sep 14;8(46):80651-80665. doi: 10.18632/oncotarget.20869. eCollection 2017 Oct 6.

6.

NRP1 transport of cancer therapeutics mediated by tumor-penetrating peptides.

Leng Q, Woodle MC, Mixson AJ.

Drugs Future. 2017 Feb;42(2):95-104. doi: 10.1358/dof.2017.042.02.2564106.

7.

Silver adducts of four-branched histidine rich peptides exhibit synergistic antifungal activity.

Leng Q, Woodle MC, Liu Y, Mixson AJ.

Biochem Biophys Res Commun. 2016 Sep 2;477(4):957-962. doi: 10.1016/j.bbrc.2016.07.008. Epub 2016 Jul 4.

8.

The neuropilin-1 receptor mediates enhanced tumor delivery of H2K polyplexes.

Leng Q, Mixson AJ.

J Gene Med. 2016 Jul;18(7):134-44. doi: 10.1002/jgm.2886.

9.

siRNA nanoparticles: the future of RNAi therapeutics for oncology?

Chou ST, Mixson AJ.

Nanomedicine (Lond). 2014 Oct;9(15):2251-4. doi: 10.2217/nnm.14.157. No abstract available.

10.

Increased tumor distribution and expression of histidine-rich plasmid polyplexes.

Leng Q, Chou ST, Scaria PV, Woodle MC, Mixson AJ.

J Gene Med. 2014 Sep-Oct;16(9-10):317-28. doi: 10.1002/jgm.2807.

11.

Direct observation of dynamic mechanical regulation of DNA condensation by environmental stimuli.

Lee A, Karcz A, Akman R, Zheng T, Kwon S, Chou ST, Sucayan S, Tricoli LJ, Hustedt JM, Leng Q, Kahn JD, Mixson AJ, Seog J.

Angew Chem Int Ed Engl. 2014 Sep 26;53(40):10631-5. doi: 10.1002/anie.201403499. Epub 2014 Aug 21.

12.

Enhancement of antifungal activity by integrin-targeting of branched histidine rich peptides.

Scaria PV, Liu Y, Leng Q, Chou ST, Mixson AJ, Woodle MC.

J Drug Target. 2014 Jul;22(6):536-42. doi: 10.3109/1061186X.2014.905948. Epub 2014 Apr 14.

13.

Enhanced silencing and stabilization of siRNA polyplexes by histidine-mediated hydrogen bonds.

Chou ST, Hom K, Zhang D, Leng Q, Tricoli LJ, Hustedt JM, Lee A, Shapiro MJ, Seog J, Kahn JD, Mixson AJ.

Biomaterials. 2014 Jan;35(2):846-55. doi: 10.1016/j.biomaterials.2013.10.019. Epub 2013 Oct 22.

14.

Surface-modified HK:siRNA nanoplexes with enhanced pharmacokinetics and tumor growth inhibition.

Chou ST, Leng Q, Scaria P, Kahn JD, Tricoli LJ, Woodle M, Mixson AJ.

Biomacromolecules. 2013 Mar 11;14(3):752-60. doi: 10.1021/bm3018356. Epub 2013 Feb 14.

15.

Buffering capacity and size of siRNA polyplexes influence cytokine levels.

Leng Q, Chou ST, Scaria PV, Woodle MC, Mixson AJ.

Mol Ther. 2012 Dec;20(12):2282-90. doi: 10.1038/mt.2012.206. Epub 2012 Oct 2.

16.

Zinc Finger Nucleases: Tailor-made for Gene Therapy.

Chou ST, Leng Q, Mixson AJ.

Drugs Future. 2012 Mar 1;37(3):183-196.

17.

Selective modification of HK peptides enhances siRNA silencing of tumor targets in vivo.

Chou ST, Leng Q, Scaria P, Woodle M, Mixson AJ.

Cancer Gene Ther. 2011 Oct;18(10):707-16. doi: 10.1038/cgt.2011.40. Epub 2011 Aug 5.

18.

Vaccines targeting the neovasculature of tumors.

Matejuk A, Leng Q, Chou ST, Mixson AJ.

Vasc Cell. 2011 Mar 8;3(1):7. doi: 10.1186/2045-824X-3-7.

19.

Peptide-based Antifungal Therapies against Emerging Infections.

Matejuk A, Leng Q, Begum MD, Woodle MC, Scaria P, Chou ST, Mixson AJ.

Drugs Future. 2010 Mar;35(3):197.

20.

Advances in Systemic siRNA Delivery.

Leng Q, Woodle MC, Lu PY, Mixson AJ.

Drugs Future. 2009 Sep;34(9):721.

21.

Leveraging therapeutic potential of multi-targeted siRNA inhibitors.

Ge Q, Xu JJ, Evans DM, Mixson AJ, Yang HY, Lu PY.

Future Med Chem. 2009 Dec;1(9):1671-81. doi: 10.4155/fmc.09.131. Review.

PMID:
21425985
22.

Human rhomboid family-1 gene silencing causes apoptosis or autophagy to epithelial cancer cells and inhibits xenograft tumor growth.

Yan Z, Zou H, Tian F, Grandis JR, Mixson AJ, Lu PY, Li LY.

Mol Cancer Ther. 2008 Jun;7(6):1355-64. doi: 10.1158/1535-7163.MCT-08-0104. Epub 2008 Jun 4.

23.

Systemic delivery of HK Raf-1 siRNA polyplexes inhibits MDA-MB-435 xenografts.

Leng Q, Scaria P, Lu P, Woodle MC, Mixson AJ.

Cancer Gene Ther. 2008 Aug;15(8):485-95. doi: 10.1038/cgt.2008.29. Epub 2008 May 16.

24.

Histidine-lysine peptides as carriers of nucleic acids.

Leng Q, Goldgeier L, Zhu J, Cambell P, Ambulos N, Mixson AJ.

Drug News Perspect. 2007 Mar;20(2):77-86. Review.

PMID:
17440630
25.

A branched histidine/lysine peptide, H2K4b, in complex with plasmids encoding antitumor proteins inhibits tumor xenografts.

Leng Q, Scaria P, Ioffe OB, Woodle M, Mixson AJ.

J Gene Med. 2006 Dec;8(12):1407-15.

PMID:
17133339
26.
27.

Transporting silence: design of carriers for siRNA to angiogenic endothelium.

Schiffelers RM, Mixson AJ, Ansari AM, Fens MH, Tang Q, Zhou Q, Xu J, Molema G, Lu PY, Scaria PV, Storm G, Woodle MC.

J Control Release. 2005 Dec 5;109(1-3):5-14. Epub 2005 Jun 24.

PMID:
15979191
28.

Small interfering RNA targeting Raf-1 inhibits tumor growth in vitro and in vivo.

Leng Q, Mixson AJ.

Cancer Gene Ther. 2005 Aug;12(8):682-90.

PMID:
15803144
29.

Highly branched HK peptides are effective carriers of siRNA.

Leng Q, Scaria P, Zhu J, Ambulos N, Campbell P, Mixson AJ.

J Gene Med. 2005 Jul;7(7):977-86.

PMID:
15772938
30.
31.

Alteration in the IL-2 signal peptide affects secretion of proteins in vitro and in vivo.

Zhang L, Leng Q, Mixson AJ.

J Gene Med. 2005 Mar;7(3):354-65.

PMID:
15619290
32.

DNA delivery to cells in culture using peptides.

Zhang L, Ambulos N, Mixson AJ.

Methods Mol Biol. 2004;245:33-52. No abstract available.

PMID:
14707368
33.

Angiogenic inhibition mediated by a DNAzyme that targets vascular endothelial growth factor receptor 2.

Zhang L, Gasper WJ, Stass SA, Ioffe OB, Davis MA, Mixson AJ.

Cancer Res. 2002 Oct 1;62(19):5463-9.

34.

Optimal transfection with the HK polymer depends on its degree of branching and the pH of endocytic vesicles.

Chen QR, Zhang L, Luther PW, Mixson AJ.

Nucleic Acids Res. 2002 Mar 15;30(6):1338-45.

35.

Targeting tumor angiogenesis with gene therapy.

Chen QR, Zhang L, Gasper W, Mixson AJ.

Mol Genet Metab. 2001 Sep-Oct;74(1-2):120-7. Review.

PMID:
11592809
36.

Branched co-polymers of histidine and lysine are efficient carriers of plasmids.

Chen QR, Zhang L, Stass SA, Mixson AJ.

Nucleic Acids Res. 2001 Mar 15;29(6):1334-40.

37.

Co-polymer of histidine and lysine markedly enhances transfection efficiency of liposomes.

Chen QR, Zhang L, Stass SA, Mixson AJ.

Gene Ther. 2000 Oct;7(19):1698-705.

38.

Antiangiogenic Gene Therapy in Cancer.

Zhang L, Chen QR, Mixson AJ.

Curr Genomics. 2000;1(2):117-133. doi: 10.2174/1389202003351535.

39.

Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice.

Chen QR, Kumar D, Stass SA, Mixson AJ.

Cancer Res. 1999 Jul 15;59(14):3308-12.

40.

Systemic gene therapy with p53 inhibits breast cancer: recent advances and therapeutic implications.

Chen QR, Mixson AJ.

Front Biosci. 1998 Sep 15;3:D997-D1004. Review.

PMID:
9740551
41.

In vivo gene therapy with a cationic polymer markedly enhances the antitumor activity of antiangiogenic genes.

Xu M, Chen QR, Kumar D, Stass SA, Mixson AJ.

Mol Genet Metab. 1998 Jul;64(3):193-7.

PMID:
9719628
42.

Gene therapy with p53 and a fragment of thrombospondin I inhibits human breast cancer in vivo.

Xu M, Kumar D, Stass SA, Mixson AJ.

Mol Genet Metab. 1998 Feb;63(2):103-9.

PMID:
9562963
43.

Parenteral gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity.

Xu M, Kumar D, Srinivas S, Detolla LJ, Yu SF, Stass SA, Mixson AJ.

Hum Gene Ther. 1997 Jan 20;8(2):177-85.

PMID:
9017421
44.

Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice.

Lesoon-Wood LA, Kim WH, Kleinman HK, Weintraub BD, Mixson AJ.

Hum Gene Ther. 1995 Apr;6(4):395-405.

PMID:
7612697
45.

ADHD and the thyroid controversy.

Hauser P, Zametkin AJ, Martinez P, Vitiello B, Matochik JA, Mixson AJ, Weintraub BD.

J Am Acad Child Adolesc Psychiatry. 1994 Jun;33(5):756-8. No abstract available.

PMID:
8056740
46.

Analysis of the binding of 3,3',5-triiodo-L-thyronine and its analogues to mutant human beta 1 thyroid hormone receptors: a model of the hormone binding site.

Cheng SY, Ransom SC, McPhie P, Bhat MK, Mixson AJ, Wintraub BD.

Biochemistry. 1994 Apr 12;33(14):4319-26.

PMID:
8155649
47.

Differential expression of mutant and normal beta T3 receptor alleles in kindreds with generalized resistance to thyroid hormone.

Mixson AJ, Hauser P, Tennyson G, Renault JC, Bodenner DL, Weintraub BD.

J Clin Invest. 1993 May;91(5):2296-300.

48.

Attention deficit-hyperactivity disorder in people with generalized resistance to thyroid hormone.

Hauser P, Zametkin AJ, Martinez P, Vitiello B, Matochik JA, Mixson AJ, Weintraub BD.

N Engl J Med. 1993 Apr 8;328(14):997-1001.

49.
50.

Thyrotropin-secreting pituitary carcinoma.

Mixson AJ, Friedman TC, Katz DA, Feuerstein IM, Taubenberger JK, Colandrea JM, Doppman JL, Oldfield EH, Weintraub BD.

J Clin Endocrinol Metab. 1993 Feb;76(2):529-33.

PMID:
8432799

Supplemental Content

Loading ...
Support Center